IMPE Abstracts

Introduction: Minipuberty describes the transient sex-specific activation of the hypothalamic-pituitary-gonadal (HPG) axis during the first 2 years in girls. Data in preterm are scarce, but It seems that the HPG axis activation is more intense and prolonged compared with full-term infants, resulting in higher sex steroid concentrations, sometimes with extreme pubertal characteristics.Clinical case: A female infant presen...

The accelerated growth phase observed during puberty depends on the combined effects of the somatotropic and gonadotropic axes. Our previous studies have demonstrated that relatively low concentrations of estradiol (20 pg/mL) and high concentrations of testosterone (10 ng/mL), potentiate the JAK2/STAT5 signaling pathway induced by GH in the human hepatic cell line (HEPG2). It is not known whether these effects are direct, or are mediated through the suppressors of cytokine sig...

Introduction: Insulin sensitivity is a marker of cardiovascular health. Young women in reproductive age with type 1 diabetes (T1D) have an increased risk of cardiovascular disease. The metabolic effects of combined oral hormonal contraception (OC) and progestin implant (implant) on insulin sensitivity in young women with T1D are unknown.Objective: To determine the effect on insulin sensitivity in young women with T1D of ...

Constitutional delay of puberty (CDP) and congenital central hypogonadism (CH) show great overlap in clinical features and in gonadotrophin and testosterone serum concentrations in boys. The gold standard to distinguish both entities relies on the assessment of pubertal stage beyond 18 years of age. The long lasting insufficient FSH activity in boys with congenital CH may result in lower AMH and inhibin B serum concentrations compared with boys with CDP....

LUM-201 (ibutamoren), an agonist of the growth hormone (GH) Secretagogue Receptor 1a (GHSR1a), is an investigational oral GH secretagogue currently in three iPGHD Phase 2 trials. The LUM-201 predictive enrichment marker (PEM) may be used to identify patients previously diagnosed with iPGHD who are likely to respond to LUM-201. PEM positivity is defined as a baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥5 ng/mL in response to a single 0.8...